All In Biotech

Drug Trial Radar · NCT07008053

BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma

BR (Bendamustine and Zuberitamab) Combined With OR (Orelabrutinib and Zuberitamab) in Treatment-naïve Marginal Zone Lymphoma: A Multicenter, Prospective Study

Last checked: Nov 19, 2026Latest source record: Jun 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

37

Planned (sponsor's estimate)

Start

Jul 2025

Primary completion

Jul 2027

Study completion Nov 2028

Sponsor

Lead sponsor
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, prospective study. The main purpose is to evaluate the efficacy and safety of BR (bendamustine and zuberitamab) combined with OR (orelabrutinib and zuberitamab) in treatment-naïve patients with marginal zone lymphoma.

Conditions

  • Marginal Zone Lymphomas

Interventions

  • BR+ORDrug

    Patients who meet the inclusion criteria will enter the treatment period, which consists of an induction phase followed by a maintenance phase. During the induction treatment period, a combined treatment of 3 cycles of the BR regimen and 3 cycles of the OR regimen will be administered, every 28-day cycle for 6 cycles. After the induction treatment, the efficacy assessment will determine whether patients with CR or PR proceed to the maintenance treatment period. Orelabrutinib monotherapy will used as maintenance therapy, every 28-day cycle for up to 24 cycles, or until disease progression/recurrence, unacceptable toxicity, death or consent withdrawal.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete response rateTime frame: From enrollment to the end of induction therapy of cycle 6 (each cycle is 28 days)

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.